Drugs / CCTx-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06281847 | Dec 2025 → Jul 2027 expected | acute myeloid leukemia | Advesya SAS | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CCTx-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06281847 ↗ |
| Target | IL1RAP | “CCTx-001 targets IL-1RAP, which is specifically expressed in leukemic cells.” NCT06281847 ↗ |